Market Introduction
Asia Pacific consists of five major countries namely China, Japan, India, Australia, and South Korea. The market is also evaluated for the Rest of Asia Pacific market. The market is driven by the factors such as increasing government initiatives, growing number of research and development activities, and increasing number of market players in the region, and growing investments by the government to enhance the domestic production for pharmaceutical products. Also, the growing partnerships among pharmaceutical companies across the regions are likely to serve vital growth opportunities for the market’s growth. Emerging markets is the major factor driving the growth of the APAC pharmaceutical intermediates market.
Countries in the Asia Pacific are facing challenges due to increasing incidences of COVID-19. As per the data of Worldometer, as of counts as of April, 2021, China reported 90,435 COVID-19 cases, while in Japan, it stood at 506,286, India recorded 13,689,453 cases, and Australia reported 29,426 confirmed cases. In India, which reported a new daily high approx. Of 27000 cases, nearly a dozen states have imposed a partial lockdown in high-risk areas. The outbreak has severely affected the tourism industry and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission. All these factors will impact the pharmaceutical intermediates market for a short period of time. The government and population in the region are more focused on the treatment of COVID 19. The hospitals, and surgical centers are open for only emergency services. China is specifically facing issues that this epidemic has caused, leading to disruption of the supply chain, projected decreases in revenue and sales within all industries, as well as the concerns of health within the production factories and other public spaces. As the medical tourism is declined in response to the pandemic to the regions like South Korea and Japan which has negative impact on the country’s revenue. In India, shutdown of the entire transportation within the country, and many provinces are establishing border restrictions within the country. This has led to paralyzed supply chains for any industry in India. All dietary supplement, including the flagship herbs and botanicals central to Ayurveda, are stopped, and the production has been ceased in the year 2020. However, in India, several hospitals are providing vitamins, supplements and other drugs to improve the treatment outcomes among covid-19 patients in India. This is likely to favor the growth of the market.
Market Overview and Dynamics
The pharmaceutical intermediates market in APAC is expected to grow from US$ 6,486.97 million in 2021 to US$ 9,057.82 million by 2028; it is estimated to grow at a CAGR of 4.9% from 2021 to 2028. Pharmaceutical intermediates are the building blocks of active pharmaceutical ingredients (APIs). These are raw materials that undergo molecular change or processing during bulk drug production. Thus, the requirement of pharmaceutical intermediates increases with the rise in demand for drugs to treat chronic diseases. The surging prevalence of infectious diseases, especially in Southeast Asia, is also likely to propel the demand for APIs in the coming years, eventually driving the growth of the pharmaceutical intermediate market. For instance, as per the Revised National Tuberculosis Control Programme Report, around 4.4 lakh patients died due to tuberculosis in India in 2018 that is 29% of the total 1.5 million deaths caused by the disease across the region. Thus, such high prevalence of chronic diseases and infectious diseases is bolstering the demand for drugs, eventually highlighting the need of pharmaceutical intermediates.
Key Market Segments
The APAC pharmaceutical intermediates market is segmented on the bases of type, application, distribution channel, and country. Based on type, the market is segmented into GMP and Non GMP. The GMP segment dominated the market in 2020 is expected to be the fastest growing during the forecast period. On the basis of application, the pharmaceutical intermediates market is segmented into antibiotics, antipyretic analgesics, vitamins, and others. The others segment dominated the market in 2020 and vitamins segment is expected to be the fastest growing during the forecast period. On the basis of distribution channel, the pharmaceutical intermediates market is segmented into distributor and direct sales. The direct sales segment dominated the market in 2020 and distributor segment is expected to be the fastest growing during the forecast period.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the pharmaceutical intermediates market in APAC are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are BASF SE; chiracon GmbH; Codexis; Dextra Laboratories Limited; Dishman Carbogen Amcis Ltd; Midas Pharma GmbH; and Sanofi are among others.
Reasons to buy report
APAC Pharmaceutical Intermediates Market Segmentation
APAC Pharmaceutical Intermediates Market -By Type
APAC Pharmaceutical Intermediates Market -By Application
APAC Pharmaceutical Intermediates Market -By Distribution Channel
APAC Pharmaceutical Intermediates Market -By Country
APAC Pharmaceutical Intermediates Market -Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 6,486.97 Million |
| Market Size by 2028 | US$ 9,057.82 Million |
| CAGR (2021 - 2028) | 4.9% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Pharmaceutical Intermediates Market is valued at US$ 6,486.97 Million in 2021, it is projected to reach US$ 9,057.82 Million by 2028.
As per our report Asia Pacific Pharmaceutical Intermediates Market, the market size is valued at US$ 6,486.97 Million in 2021, projecting it to reach US$ 9,057.82 Million by 2028. This translates to a CAGR of approximately 4.9% during the forecast period.
The Asia Pacific Pharmaceutical Intermediates Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Pharmaceutical Intermediates Market report:
The Asia Pacific Pharmaceutical Intermediates Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Pharmaceutical Intermediates Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Pharmaceutical Intermediates Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Pharmaceutical Intermediates Market
